Skip to main content
SpringerLink
Log in

Bioanalytical Comparison of Transdermal Delivery of Tizanidine from Different Nanovesicular Carriers

  • Research Article
  • Published:
Journal of Pharmaceutical Innovation Aims and scope Submit manuscript

Abstract

Purpose

Tizanidine (TZN) is used for the management of muscle spasms. Oral TZN is liable to first-pass metabolism and interindividual variation. Transdermal drug delivery systems (TDDS) are gaining research attention as an alternative route. The aim of this study is the bioanalytical comparison of the oral route and two TDDS, bilosomes and aspasomes.

Methods

TZN-loaded bilosomes and aspasomes were applied to mice. The plasma concentration of TZN was determined in mice plasma post application by in-house developed HPLC method. Results were compared to those obtained post an equal oral dose. Pharmacokinetic parameters were deduced and statistically compared.

Results

The TDDS route significantly enhanced the bioavailability and plasma concentration of TZN (p < 0.0009; CL = 95). The drug half-life (t1/2) significantly increased (< 0.0001; CL = 95) when using the TDDS instead of the oral route. Among the TDDS vesicles, the bilosomes significantly enhance bioavailability and Cmax over aspasomes (p < 0.0316; CL = 95). Both vesicles were not statistically different in terms of extending the drug half-life.

Conclusions

In conclusion, the bioanalytical comparison revealed that the TDDS can overcome the first-pass effect of TZN and enhances its bioavailability over the oral route. Bilosomes were more efficient than aspasomes for enhancing the TZN bioavailability. Both vesicular formulas were equivalent for extending the half-life of the drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Farrell MC, Biaggioni I, Shibao CA. Neurogenic orthostatic hypotension induced by tizanidine. Clin Auton Res. 2019:1–3.

  2. Simpson S, Huycke LI. Multiple sclerosis—what occupational health nurses need to know. AAOHN J. 2006;54(11):469–78.

    Article  Google Scholar 

  3. Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther. 2004;75(4):331–41.

    Article  CAS  Google Scholar 

  4. Zhou S-F, Wang B, Yang L-P, Liu J-P. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2010;42(2):268–354. https://doi.org/10.3109/03602530903286476.

    Article  CAS  PubMed  Google Scholar 

  5. Wagstaff AJ, Bryson HM. Tizanidine. Drugs. 1997;53(3):435–52. https://doi.org/10.2165/00003495-199753030-00007.

    Article  CAS  PubMed  Google Scholar 

  6. Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. 1997;54(6):731–6. https://doi.org/10.1001/archneur.1997.00550180049011.

    Article  CAS  PubMed  Google Scholar 

  7. Emre M, Leslie GC, Muir C, Part NJ, Pokorny R, Roberts RC. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry. 1994;57(11):1355–9. https://doi.org/10.1136/jnnp.57.11.1355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Henney HR III, Runyan JD. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients. Int J Clin Pract. 2008;62(2):314–24. https://doi.org/10.1111/j.1742-1241.2007.01660.x.

    Article  CAS  PubMed  Google Scholar 

  9. Backman JT, Schröder MT, Neuvonen PJ. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol. 2008;64(1):17–24.

    Article  CAS  Google Scholar 

  10. Thakkar H, Pandya K, Patel B. Microneedle-mediated transdermal delivery of tizanidine hydrochloride. In: Jain KK, editor. Drug Delivery Systems. New York, NY: Springer New York; 2020. p. 239–58.

    Chapter  Google Scholar 

  11. Khalil RM, Abdelbary A, Kocova El-Arini S, Basha M, El-Hashemy HA. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. J Liposome Res. 2019;29(2):171–82.

    Article  CAS  Google Scholar 

  12. Khalil RM, Abdelbary A, Kocova El Arini S, Basha M, El-Hashemy HA, Farouk F. Development of tizanidine loaded aspasomes as transdermal delivery system: ex-vivo and in-vivo evaluation. J liposome Res. 2019 (Published online: 08 Nov 2019):1–36.

  13. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S. Quantification of tizanidine in human plasma by liquid chromatography coupled to tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006;20(15):2286–92.

    Article  CAS  Google Scholar 

  14. Ulu ST. Sensitive spectrofluorimetric determination of tizanidine in pharmaceutical preparations, human plasma and urine through derivatization with dansyl chloride. Luminescence. 2012;27(5):426–30. https://doi.org/10.1002/bio.1367.

    Article  CAS  PubMed  Google Scholar 

  15. Khalil RM, Abdelbary A, Arini SKE, Basha M, El-Hashemy HA, Farouk F. Development of tizanidine loaded aspasomes as transdermal delivery system: ex-vivo and in-vivo evaluation. J Liposome Res. 2019:1–11.

  16. Use CfMPfH. Guideline on bioanalytical method validation. European Medicines Agency EMEA: CHMP/EWP/192217/2009, 1–22. (cited 2011 August 01). Available from: www.ema.europa.eu/ema/pages/includes/document/open_document.jsp.

  17. Silvia RMKAA, Hadeer KEAMB, Faroukc AE-HF. Development of tizanidine loaded aspasomes as transdermal delivery system: ex-vivo and in-vivo evaluation

  18. Ahuja S, Dong M. Handbook of pharmaceutical analysis by HPLC: Elsevier; 2005.

  19. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br J Clin Pharmacol. 2004;57(3):349–53. https://doi.org/10.1046/j.1365-2125.2003.02028.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Pavlović N, Goločorbin-Kon S, Ðanić M, Stanimirov B, Al-Salami H, Stankov K, et al. Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles. Front Pharmacol. 2018;9(1283). https://doi.org/10.3389/fphar.2018.01283.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ahram Canadian University, Cairo, Egypt

    Faten Farouk

  2. Department of Pharmaceutical Technology, National Research Centre, Cairo, Egypt

    Rawia M. Khalil, Silvia Kocova El Arini, Mona Basha & Hadeer A. El-Hashemy

  3. Department of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, Egypt

    Ahmed Abdelbary

Authors
  1. Faten Farouk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rawia M. Khalil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed Abdelbary
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia Kocova El Arini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mona Basha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hadeer A. El-Hashemy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faten Farouk.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Farouk, F., Khalil, R.M., Abdelbary, A. et al. Bioanalytical Comparison of Transdermal Delivery of Tizanidine from Different Nanovesicular Carriers. J Pharm Innov 16, 384–390 (2021). https://doi.org/10.1007/s12247-020-09447-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12247-020-09447-z

Keywords

Search

Navigation